Table 4: Terminated or Withdrawn Ketogenic Diet Intervention and Cancer Clinical Trials Overview

Trial ID	Status	Name	Design	N	Cancer Type	Diet	Length	Treatment	Purpose
	Terminated (Recruitment challenges due to competition with another microbiome trial, pt refusal, and poor tolerance of oral DPD)	Evaluating a Ketogenic Diet Concomitant to Nivolumab and	Parallel Assignment	n=3	Renal cell carcinoma	KD: <40 g/day CHO, w/ oral liquid ketone supplement BHB monoester (2 tablespoons three times per day for third arm)	1 year	Immunotherapy	Evaluate the objective response rate (including partial and complete responses) to the combination of Nivolumab and Ipilimumab administered alongside either a ketogenic diet (continuous or intermittent) or a standard diet, with or without betahydroxybutyrate (BHB) supplementation.
	Terminated (low accrual)	Concurrent	Single Group Assignment	n=5	Pancreatic	KD: 4:1 [fat:protein+CHO]	5 weeks	Chemoradiation	Examine the safety and tolerability of KD combined with chemotherapy and radiation therapy in pts with pancreatic cancer.
	Terminated (slow recruitment, lack of funding, transferred PI)	Prostate Cancer	RCT	n=45	Prostate	,		Androgen deprivation therapy	Test the hypothesis that low carbohydrate diet will minimize metabolic consequences of androgen deprivation therapy.
NCT03328858	Terminated (PI unavailable and pts lost to follow up)	Children With	Single Group Assignment	n=20	Brain tumor (medulloblastoma high-grade glioma, low-grade glioma, and ependymoma)	KD: 4:1 [fat:protein+CHO]	1 year	Chemoradiation	Evaluate the effects of KD on QoL and tumor size in pts (pediatric) with malignant or recurrent/refractory brain tumors.
	,		Group	n=0	Mantle cell lymphoma	N/A	12 weeks	N/A	To assess the feasibility and adherence to a KD in pts with low tumor burden, treatmentnaïve mantle cell lymphoma, while monitoring metabolic, tumor, and body composition changes.
	Withdrawn (lack of funding)		Group	n=0	Brain tumor (regressive or refectory)	KD: 2:1 to 4:1 [fat:protein+CHO] (adjusted based upon BHB levels and adherence)	28 days	N/A	To determine the feasibility of KD of classic, strict KD in pediatric pts with recurrent or progressive and refectory brain tumors and evaluate

									survival progression and tumor response.
	Terminated (poor accrual and pt adherence)		Single Group Assignment	n=5	Non-small lung cancer	KD: 4:1 [fat:protein+CHO]		Chemoradiation	Investigate if KD is tolerable and safe when combine with chemotherapy and radiation therapy in pts with lung cancer.
NCT02046187	(excessive protocol deviations due to	_	Single Group Assignment	n=14	Glioblastoma multiforme	KD: 4:1 [fat:protein+CHO] (on chemoradiation), MAD: (on chemotherapy)		Chemoradiation	Evaluates if KD started after surgical resection can be safely maintained and enhance the effectiveness of standard chemoradiotherapy in pts with glioblastoma, and to assess survival, recurrence, and quality of life.
	Terminated (low accrual)	Ketogenic Diet Phase 1 for Head & Neck Cancer	Single Group Assignment		Squamous cell carcinoma	KD: 4:1 [fat:protein+CHO]			Determine whether a very low carbohydrate (ketogenic) diet is safe and tolerable for pts undergoing concurrent chemotherapy and radiation therapy for head and neck cancer.
	Terminated (low accrual)	Reducing Insulin, Growth Hormones, and Tumors (RIGHT)	RCT	n=3	Non-small cell adenocarcinoma, squamous cell carcinoma	KD: 65% fats, starchy vegetables, fruits, berries, and legumes (<10% caloric intake)	24 weeks	N/A	Compare the effects of a low-carbohydrate, high-fat ketogenic diet and a low-fat, high-carbohydrate plant-based diet on biomarkers of inflammation, insulin resistance, and cancer progression in pts with advanced lung cancer.

KD=ketogenic diet

AD=atkin's diet

MAD=modified atkin's diet

CHO=carbohydrate

RCT=randomized controlled trial